Ainos (AIMD)
NASDAQ:AIMD
AIMD Stock Chart & Stats
$2.28
$0.28(14.00%)
At close: 4:00 PM EST
$2.28
$0.28(14.00%)
Day’s Range― - ―
52-Week Range$1.26 - $4.50
Previous CloseN/A
Volume448.92K
Average Volume (3M)78.00K
Market Cap
$10.46M
Enterprise Value$16.75M
Total Cash (Recent Filing)$417.35K
Total Debt (Recent Filing)$11.00M
Price to Earnings (P/E)―
Beta1.84
Next Earnings
May 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.85
Shares Outstanding7,266,011
10 Day Avg. Volume93,591
30 Day Avg. Volume77,998
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.93
Price to Sales (P/S)56.41
P/FCF Ratio-1.51
Enterprise Value/Market Cap1.60
Enterprise Value/Revenue134.89
Enterprise Value/Gross Profit162.74
Enterprise Value/Ebitda-1.81
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
High Gross MarginA reported gross margin of ~83% indicates the AI Nose hardware and related services can capture high unit economics on product revenue. Sustained high gross margins support future margin expansion as revenue scales and enable funding of R&D and software development without relying solely on external financing.
Strategic Distribution AgreementA multi-year distribution deal with Trusval establishes structured regional sales channels and initial exclusivity, which can materially reduce commercial execution risk, accelerate customer access, and create repeatable revenue pathways that support scaling beyond direct sales.
Platform Strategy & HW/SW SeparationA layered SmellTech architecture separating edge hardware and ScentAI software positions the company to shift from one-off device sales to recurring, intelligence-driven software services. This structural move supports higher lifetime customer value and more predictable recurring revenue over time.
Bears Say
Persistent Cash BurnSustained negative operating and free cash flow of roughly -$4.6M implies continued reliance on external financing. Over the medium term, ongoing cash burn increases dilution or debt risk and constrains the firm’s ability to invest in commercialization and R&D without worsening the balance sheet.
Rising Leverage And Weak Equity BaseMaterial increase in leverage and declining equity reduce financial flexibility and raise refinancing risk. With debt-to-equity up markedly, interest and covenant pressures could limit strategic options and make the firm more vulnerable during revenue shortfalls or higher rates.
Volatile & Insufficient Revenue Vs. CostsRevenue remains tiny and volatile relative to fixed operating costs, producing deeply negative net margins. Until revenue scale materially outpaces operating expenses, profitability is unlikely; the mismatch risks repeated dilution or cost cuts that could slow product commercialization.
Ainos News
AIMD FAQ
What was Ainos’s price range in the past 12 months?
Ainos lowest stock price was $1.26 and its highest was $4.50 in the past 12 months.
What is Ainos’s market cap?
Ainos’s market cap is $10.46M.
When is Ainos’s upcoming earnings report date?
Ainos’s upcoming earnings report date is May 18, 2026 which is in 44 days.
How were Ainos’s earnings last quarter?
Ainos released its earnings results on Mar 30, 2026. The company reported -$0.853 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.853.
Is Ainos overvalued?
According to Wall Street analysts Ainos’s price is currently Overvalued.
Does Ainos pay dividends?
Ainos does not currently pay dividends.
What is Ainos’s EPS estimate?
Ainos’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Ainos have?
Ainos has 7,266,011 shares outstanding.
What happened to Ainos’s price movement after its last earnings report?
Ainos reported an EPS of -$0.853 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.878%.
Which hedge fund is a major shareholder of Ainos?
Currently, no hedge funds are holding shares in AIMD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Ainos
Ainos, Inc., a healthcare company, engages in the developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. The company was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. Ainos, Inc. was incorporated in 1984 and is based in San Diego, California.
Technical Analysis
Bioline RX Ltd Sponsored ADR
―
Soligenix
―
Chemomab Therapeutics
―
―
FibroBiologics, Inc.
―